AN2 Therapeutics, Inc. ANTX 深 沪
等待开盘 02-12 09:30:00 美东时间
1.07
-0.030
-2.73%
华盛通- 最 高1.09
- 今 开1.09
- 成交量 1.61万股
- 最 低 1.07
- 昨 收 1.10
- 总市值 2932.02万
- 52周最高 1.55
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 1.00
- 委 比 90.24%
- 总股本 2740.20万
- 历史最高 23.58
- 量 比 0.51
- 振 幅 1.82%
- 历史最低 0.87
- 每 手 1
- 风险率 0.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The FDA Clears Oregon Health & Science University's Investigational New Drug Application To Proceed With Investigator-Initiated Trial Of AN2 Therapeutics' Epetraborole For Mycobacterium Abscessus Lung Disease, Patient Enrollment To Start In Q1 2026
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapiesLed by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop, trial will focus on early-stage,
01-12 20:10
AN2 Therapeutics reports Q3 results
AN2 Therapeutics press release (ANTX): Q3 net loss was $9.4 million. The Company had cash, cash equivalents and investments of $65.1 million at September 30, 2025. More on AN2 Therapeutics Seeking Alp...
2025-11-13 23:20
AN2 Therapeutics Q3 EPS $(0.31) Misses $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.30) by 4.73 percent. This is a 27.91 percent increase over losses of $(0.43) per share from
2025-11-13 05:30
AN2 Therapeutics Announces Collaboration Agreement With GSK To Develop New Therapies For TB
AN2 awarded third year of funding from Gates FoundationAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a
2025-11-10 20:11
AN2 Therapeutics Q2 EPS $(0.21) Beats $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30.69 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
2025-08-13 04:20
AN2 Therapeutics Unveils Updated Investor Presentation
AN2 Therapeutics, Inc. ( ($ANTX) ) just unveiled an announcement. On June 11, 2...
2025-06-11 19:59
AN2 Therapeutics Elects New Directors at Annual Meeting
AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an announcement. On May 22, 2025,...
2025-05-28 05:09
AN2 Therapeutics Q1 GAAP EPS $(0.35) Misses $(0.26) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
2025-05-14 06:01
快讯 | AN2 Therapeutics Inc：预计现金流将资助运营至2028年
AN2 Therapeutics Inc: Cash Runway Anticipated to Fund Operations Into 2028
2025-05-14 04:02
快讯 | AN2 Therapeutics报告2025财年第一季度财务业绩以及近期的业务和科学亮点
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Busine...
2025-05-14 04:01
